Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1205-1215

  Juhász, Erzsébet ^a   Kim, Joo Hang ^b   Klingelschmitt, Gaëlle ^c   Walzer, Stefan ^c,d  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^b Yonsei University College of Medicine   (South Korea)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d MArS Market Access and Pricing Strategy GmbH   (Germany)

Author keywords

Erlotinib; Health related quality of life; Metastatic non small cell lung cancer

Indexed keywords

ERLOTINIB; PLACEBO;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; DYSPNEA; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PARONYCHIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EXANTHEMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875706413     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.006     Document Type: Article

References (38)

1. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592
2. C.F. Mountain The international system for staging lung cancer Semin Surg Oncol 18 2000 106 115
3. D. Veale, N. Kerr, G.J. Gibson, P.J. Kelly, and A.L. Harris The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival Br J Cancer 68 1993 162 165
4. V. Rusch, D. Klimstra, E. Venkatraman, P.W. Pisters, J. Langenfeld, and E. Dmitrovsky Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression Clin Cancer Res 3 1997 515 522
5. G. Fontanini, M. De Laurentiis, and S. Vignati Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival Clin Cancer Res 4 1998 241 249
6. G. Selvaggi, S. Novello, and V. Torri Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann Oncol 15 2004 28 32
7. F.R. Hirsch, M. Varella-Garcia, and P.A. Bunn Jr. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 2003 3798 3807
8. D.E.B. Swinson, G. Cox, and K.J. O'Byrne Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer Br J Cancer 91 2004 1301 1307
9. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl. 4 2001 S9 S15
10. M.B. Lustberg, and M.J. Edelman Optimal duration of chemotherapy in advanced non-small cell lung cancer Curr Treat Options Oncol 8 2007 38 46
11. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
12. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 2009 1227 1234
13. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
14. A. Sandler, J. Yi, and S. Dahlberg Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer J Thorac Oncol 5 2010 1416 1423
15. C. Gridelli, P. Maione, and A. Rossi Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 14 2009 137 147
16. F. Grossi, M. Aita, and A. Follador Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature Oncologist 12 2007 451 464
17. M. Rinaldi, O. Belvedere, C. Cauchi, C. Defferrari, G. Viola, and F. Grossi Maintenance chemotherapy in non-small cell lung cancer Ann Oncol 17 Suppl. 2 2006 ii67 ii70
18. M. Reck, T. Mok, J. Wolf, D. Heigener, and Y.L. Wu Reviewing the safety of erlotinib in non-small cell lung cancer Expert Opin Drug Saf 10 2011 147 157
19. European Medicines Agency. Committee for Medicinal Products for Human use post-authorisation summary of positive opinion for Tarceva. http://www.emea.europa.eu/pdfs/human/opinion/51116606en.pdf.
20. US Food and Drug Administration. Tarceva. Label and approval history. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails. [Accessed 22 October 2010].
21. T. Hensing, D. Cella, and S. Yount The impact of ECOG performance status on quality of life symptoms in patients with advanced lung cancer J Clin Oncol (Meeting Abstracts) 23 2005 753s (abs. 8099)
22. F. Cappuzzo, T. Ciuleanu, and L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
23. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Version 4. Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997.
24. D. Cella, D.T. Eton, and D.L. Fairclough What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592 J Clin Epidemiol 55 2002 285 295
25. D. Cella, E.A. Hahn, and K. Dineen Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening Qual Life Res 11 2002 207 221
26. J. Ringash, A. Bezjak, B. O'Sullivan, and D.A. Redelmeier Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients Qual Life Res 13 2004 725 733
27. A. Rozzi, C. Nardoni, and M. Corona Erlotinib as third-line therapy in advanced/metastatic non small cell lung cancer (NSCLC): results from a single-centre experience J Thorac Oncol 3 Suppl. 1 2008 S83 S84 (abs. 231P)
28. V. Alberola, O. Gallego, and G. López-Vivanco Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study J Clin Oncol (Meeting Abstracts) 25 2007 695s (abs. 18140)
29. D.F. Cella, A.E. Bonomi, S.R. Lloyd, D.S. Tulsky, E. Kaplan, and P. Bonomi Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument Lung Cancer 12 1995 199 220
30. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
31. P.M. Fidias, S.R. Dakhil, and A.P. Lyss Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 2009 591 598
32. R.M. Gaafar, V. Surmont, and G. Scagliotti A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03) J Clin Oncol (Meeting Abstracts) 2010 28 abs. 7518
33. F.F. Kabbinavar, V.A. Miller, B.E. Johnson, P.G. O'Connor, C. Soh the ATLAS Investigators Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol (Meeting Abstracts) 2010 28 abs. 7526
34. M. Perol, C. Chouaid, and B.J. Milleron Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study J Clin Oncol (Meeting Abstracts) 2010 28 abs. 7507
35. European Medicines Agency. Committee for Medicinal Products for Human use post-authorisation summary of positive opinion for Alimta. http://www.emea. europa.eu/pdfs/human/opinion/Alimta-9292908en.pdf.
36. Casciano R, Bischoff H, Nuijten M, Malangone E, Ray J. Maintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: Indirect comparison applying real-life outcomes. Presented at the ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November 2010.
37. R.S. Herbst, D. Prager, and R. Hermann TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
38. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation trial J Clin Oncol 25 2007 1545 1552